VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025. Fireside Chat Presentation Details: Date: Wednesday, May 21, 2025 Time: 10:30-10:55 AM ...

Xenon Pharmaceuticals (XENE) reported a loss of 83 cents per share for the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 94 cents. The company had incurred a loss of 62 cents per share in the year-ago quarter.The company generated revenues of $7.5 million in the first quarter, which marginally missed the Zacks Consensus Estimate of $8 million. In the year-ago quarter, Xenon did not generate any revenues. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar ...

Xenon Pharmaceuticals (XENE) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Chad Fugere - VP - IRIan Mortimer - President and CEOChristopher Kenney - Chief Medical OfficerSherry Aulin - CFOBrian Abrahams - MD & Global Sector Head - Health Care ResearchBasma Radwan - Equity Research AssociateDylan Shindler - Biotechnology Equity Research AssociateAndrew Tsai - SVP Conference Call Participants Paul Matteis - AnalystTessa Romero - Equity AnalystBrian Skorney - Senior Research AnalystMyles ...

Xenon Pharmaceuticals (XENE) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q1 twenty twenty five Xenon Pharmaceuticals Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Thank you. I would now like to turn the call over to Chad Fougier, Xen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 ...

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update VANCOUVER, BC and BOSTON, MA, May 12, 2025 – Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience- focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "We continue to make steady progress across our Phase 3 epilepsy program, with pati ...

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, anticipated in ...

VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information:  Date:Monday, May 12, 2025  Time:4:30 p ...

Xenon Pharmaceuticals (XENE) closed the last trading session at $38.28, gaining 30.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $56.71 indicates a 48.2% upside potential.The average comprises 14 short-term price targets ranging from a low of $42 to a high of $65, with a standard deviation of $6.73. While the lowest estimate indicates an increase of 9.7% from the current price ...

文章核心观点 公司宣布向四名新非管理人员授予股权奖励，包括78,600份股票期权和1,800份绩效股票单位 [1] 股权奖励授予情况 - 授予对象为四名新非管理人员 [1] - 授予内容包括78,600份股票期权和1,800份绩效股票单位 [1] - 授予经公司董事会薪酬委员会批准，生效日期为2025年5月2日，依据纳斯达克上市规则5635(c)(4)作为员工入职诱因授予 [1] 股票期权情况 - 行使价格为每股38.28美元，与2025年5月2日授予日公司普通股收盘价相同 [2] - 分四年归属，员工入职一周年时归属25%，之后每月最后一天归属剩余期权的1/36，需员工持续为公司服务 [2] - 每份期权有效期10年，受股票期权协议和公司2025年诱因股权奖励计划条款约束 [2] 绩效股票单位情况 - 基于约三年绩效期内达成预定里程碑目标归属（若有），需员工持续为公司服务 [2] - 每份授予受绩效股票单位奖励协议和公司2025年诱因股权奖励计划条款约束 [2] 公司简介 - 是专注神经科学的生物制药公司，致力于发现、开发和提供改变生活的疗法 [3] - 推进离子通道产品组合，以满足癫痫和抑郁症等未满足的医疗需求 [3] - 新型、高效、选择性Kv7钾通道开放剂Azetukalner是针对多种适应症处于后期临床开发的最先进、经临床验证的钾通道调节剂 [3] 联系方式 - 投资者联系：副总裁Chad Fugere，电话(857) 675-7275，邮箱investors@xenon-pharma.com [5] - 媒体联系：高级副总裁Colleen Alabiso，电话(617) 671-9238，邮箱media@xenon-pharma.com [5]